Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis - Business Wire

Takeda announced positive results in a Phase 2 study of TAK-279, an oral, once-daily TYK2 inhibitor, in people with moderate to severe plaque psoriasis.Business Wire
In retrospect, we say this was a bargain. Takeda reveals first data from $4 billion autoimmune disease pillThe Boston Globe
Tada’s $4 billion Psoriasis pill helps clear skin in mid-stage study.Bloomberg
Takeda raised by BofA to buy on growth prospects and debt repayment (NYSE:TAK)Seeking Alpha
See full coverage on Google News

Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis – Business Wire